Login to Your Account

Satellite Strategy Working for Isis

Pfizer Nabs Phase II-Stage Skin Scarring Drug in Excaliard Buy

By Jennifer Boggs
Managing Editor

Wednesday, November 23, 2011
Privately held Excaliard Pharmaceuticals Inc., which started out the year by reporting positive Phase II data for its lead anti-scarring compound, EXC 001, is ending 2011 with an acquisition by pharma giant Pfizer Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription